High in vitro and in vivo synergistic activity between mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC

Significant rational is available for specific targeting of PI3K/AKT/mTOR pathway in the treatment of non-small cell lung cancer (NSCLC). However, almost all clinical trials that have evaluated Pi3K pathway-based monotherapies/combinations did not observe an improvement of patient’s outcome. The aim...

Descripción completa

Detalles Bibliográficos
Autores principales: Montaudon, Elodie, El Botty, Rania, Vacher, Sophie, Déas, Olivier, Naguez, Adnan, Chateau-Joubert, Sophie, Treguer, Damien, de Plater, Ludmilla, Zemoura, Leïla, Némati, Fariba, Nicolas, André, Chapelier, Alain, Livartowski, Alain, Cairo, Stefano, Daniel, Catherine, Brevet, Marie, Marangoni, Elisabetta, Meseure, Didier, Roman-Roman, Sergio, Bieche, Ivan, Girard, Nicolas, Decaudin, Didier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057272/
https://www.ncbi.nlm.nih.gov/pubmed/33889306
http://dx.doi.org/10.18632/oncotarget.27930

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057272/
https://www.ncbi.nlm.nih.gov/pubmed/33889306
http://dx.doi.org/10.18632/oncotarget.27930

Ejemplares similares